Fosun Pharma grants stock options, advances cancer drug development

Shanghai Fosun Pharmaceutical Group has successfully completed the initial grant of its 2025 A-share stock option incentive plan, registering 4,446,400 A-share stock options on December 2, 2025, to 182 grantees. The exercise price for these options is RMB 27.93 per share, with the options sourced from the company's repurchased A-shares. The total estimated accounting cost for the incentive plan is RMB 1,211万元, spread across 2025-2028.

Concurrently, Fosun Pharma's subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., received approval from the National Medical Products Administration for FXS0887 tablets to proceed with Phase I clinical trials in China for advanced malignant solid tumors. FXS0887, an independently developed oral small molecule innovative drug, targets ATR kinase activity to inhibit tumor growth.

As of October 2025, the cumulative research and development investment for FXS0887 by Fosun Pharma totals approximately RMB 0.44亿元 (unaudited). There are currently no other small molecule inhibitors with the same target approved globally for monotherapy or combination therapy.